BSN Tracker

venetoclax

Brand: Venclexta, Venclyxto

⚠ BBW ISMP High Alert Prototype Drug
Drug Class: BCL-2 inhibitor
Drug Family: antineoplastic
Subclass: selective BCL-2 inhibitor (BH3 mimetic)
Organ Systems: hematology-oncology

Mechanism of Action

Binds to BCL-2 with high affinity and selectivity, displacing pro-apoptotic proteins (BAX, BAK) that BCL-2 normally sequesters; releases these proteins to activate the intrinsic apoptosis pathway; CLL cells overexpress BCL-2 making them highly sensitive.

BCL-2 antiapoptotic protein

Indications

  • chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
  • acute myeloid leukemia (AML) — in combination with azacitidine or decitabine, or low-dose cytarabine (in adults ineligible for intensive induction)

Contraindications

  • venetoclax hypersensitivity
  • concurrent use of strong CYP3A4 inhibitors at initiation/ramp-up phase (extreme TLS risk)

Adverse Effects

Common

  • neutropenia
  • diarrhea
  • nausea
  • anemia
  • fatigue

Serious

  • tumor lysis syndrome (TLS — potentially fatal, especially during ramp-up)
  • myelosuppression
  • serious infections (from neutropenia + immunosuppression)

Pharmacokinetics (ADME)

Absorption oral; administration with food (low-fat or high-fat meal) required — low-fat meal increases Cmax 3-fold, high-fat meal ~5-fold vs fasting
Distribution widely distributed; highly protein-bound
Metabolism hepatic CYP3A4/P-gp (primary); active metabolite M27 (weak)
Excretion fecal (>99.9%)
Half-life 26 hours
Onset days to weeks
Peak 5–8 hours
Duration once-daily
Protein Binding >99%
Vd large

Drug Interactions

Drug / Agent Mechanism Severity
strong CYP3A4 inhibitors (posaconazole, voriconazole, clarithromycin) increase venetoclax AUC 5–7-fold; venetoclax dose must be reduced by 75%; TLS risk is extreme major
rifampin (strong CYP3A4 inducer) reduces venetoclax AUC >71%; avoid combination major
P-gp inhibitors increase venetoclax exposure; adjust dose major

Nursing Considerations

  1. TLS prevention is paramount: assess baseline risk, ensure adequate hydration (1.8–2.4 L/day), administer allopurinol 2–3 days before ramp-up, monitor uric acid, potassium, phosphate, creatinine at regular intervals during ramp-up.
  2. Ramp-up dosing is mandatory: 20 mg → 50 mg → 100 mg → 200 mg → 400 mg (final dose), with 1 week at each dose level; do NOT skip ramp-up.
  3. CYP3A4 inhibitors dramatically increase venetoclax exposure; any azole antifungal, macrolide, or other CYP3A4 inhibitor requires venetoclax dose reduction.
  4. Administer with food; refrigerate and protect from light; daily at approximately the same time each day.

Clinical Pearls

  • Venetoclax represents the most dramatic single-drug activity seen in CLL treatment — objective response rates of 79% as monotherapy and >90% in combination regimens; the BCL-2 inhibitor concept validates that targeting anti-apoptotic proteins can treat BCL-2-dependent malignancies.
  • TLS risk with venetoclax is related to the tumor burden and BCL-2 dependence of the cancer cells; the week-long ramp-up schedule was specifically designed to allow incremental tumor kill while managing TLS — do not shortcut this schedule.

Safety Profile

Pregnancy contraindicated
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required
Guideline Update pending

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Acute Myeloid Leukemia (AML) — In Combination With Azacitidine Or Decitabine, Or Low-dose Cytarabine (in Adults Ineligible For Intensive Induction) BCL-2 Inhibitor Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL)
← Back to Medications